The experimental enhancement of TGFβ/Activin signaling in animal models exacerbates pulmonary vascular remodeling mimicking PAH pathology [8] and reduction of TGFβ signaling through genetic or pharmacological intervention was efficacious in reversing the vascular remodeling in PAH animal models [5, 9]. The gene discussed is INHBE; the disease is pulmonary arterial hypertension.